NFE2L2 mutations enhance radioresistance in head and neck cancer by modulating intratumoral myeloid cells.
Sign Up to like & getrecommendations! Published in 2023 at "Cancer research"
DOI: 10.1158/0008-5472.can-22-1903
Abstract: Radiotherapy is one of the primary treatments of head and neck squamous cell carcinoma (HNSCC), which has a high risk of locoregional failure (LRF). Presently, there is no reliable predictive biomarker of radioresistance in HNSCC.… read more here.
Keywords: head neck; nfe2l2 mutations; intratumoral myeloid; cancer ... See more keywords
KEAP1/NFE2L2 Mutations of Liquid Biopsy as Prognostic Biomarkers in Patients With Advanced Non-Small Cell Lung Cancer: Results From Two Multicenter, Randomized Clinical Trials
Sign Up to like & getrecommendations! Published in 2021 at "Frontiers in Oncology"
DOI: 10.3389/fonc.2021.659200
Abstract: Purpose The KEAP1-NFE2L2 (Kelch-like ECH-associated protein 1 (KEAP1)-Nuclear factor (erythroid-derived 2)-like 2 (NFE2L2)) mutations are associated with resistance to chemotherapy or immunotherapy in non-small cell lung cancer (NSCLC). Conversely, it has been reported that NFE2L2… read more here.
Keywords: keap1 nfe2l2; nfe2l2 mutations; non small; cancer ... See more keywords